Mild Traumatic Brain Injury Treatment Market Size
Study Period | 2019 - 2029 |
Base Year For Estimation | 2023 |
Forecast Data Period | 2024 - 2029 |
CAGR | 3.80 % |
Fastest Growing Market | Asia Pacific |
Largest Market | North America |
Major Players*Disclaimer: Major Players sorted in no particular order |
Mild Traumatic Brain Injury Treatment Market Analysis
The Mild Traumatic Brain Injury Treatment market is expected to witness a CAGR of 3.8% during the forecast period. Certain factors that are driving the market growth include increasing incidence of mild traumatic brain injuries, and ongoing product development and approval.
Mild traumatic brain injury (MTBI) is a frequent medical condition, and some patients report long-lasting problems after MTBI. In order to prevent MTBI, knowledge of epidemiology is an important, and potential bias in studies should be explored. Traumatic brain injury (TBI) is a complex injury comprising a spectrum from mild TBI (MTBI) with low risk of persistent disability, to the most severe TBI with devastating brain damage. However, MTBI constitutes 80-90 % of all TBI. Therefore the rising incidences and injuries being caused to the brain worldwide resulting in a high prevalence of target disorders are expected to impact the market in a positive manner.
Mild Traumatic Brain Injury Treatment Market Trends
This section covers the major market trends shaping the Mild Traumatic Brain Injury Treatment Market according to our research experts:
Hospital is Expected to Hold Significant Market Share in the End User Segment
The therapy for mild traumatic brain injury treatment usually begins in the hospital and continues at an inpatient rehabilitation unit, a residential treatment facility, or through outpatient services. The type and duration of rehabilitation are different for everyone, depending on the severity of the brain injury and what part of the brain was injured. People with mild traumatic brain injuries may also have other injuries that need to be addressed.
Additional treatments in the emergency room or intensive care unit of a hospital generally focus on minimizing secondary damage due to inflammation, bleeding, or reduced oxygen supply to the brain.
North America Dominates the Market and Expected to do Same in the Forecast Period
Traumatic brain injury (TBI), also known as acquired brain injury, head injury, or brain injury, causes substantial disability and mortality in the American population. It occurs when a sudden trauma damages the brain and disrupts normal brain function. TBI often has profound physical, psychological, cognitive, emotional, and social effects on the lives of American people. Mild TBI appears to be vastly under-diagnosed in the setting of systemic trauma, even in trauma centers. According to the CDC, there were approximately 2.8 million TBI-related emergency department visits, hospitalizations, and deaths in the United States in 2015. Hence, the rising prevalence of MTBI is expected to drive the overall growth of the market across the entire region.
Mild Traumatic Brain Injury Treatment Industry Overview
The global Mild Traumatic Brain Injury Treatment market is highly competitive and consists of a number of major players. Companies like Grace Laboratories LLC., Integra LifeSciences Corporation, Medtronic PLC, Neuren Pharmaceuticals Ltd., NeuroVive Pharmaceutical AB , Stemedica Cell Technologies Inc., TEVA Pharmaceutical Industries Ltd., Vasopharm GmbH, among others, hold the substantial market share in the Mild Traumatic Brain Injury Treatment market.
Mild Traumatic Brain Injury Treatment Market Leaders
-
NeuroVive Pharmaceutical AB
-
TEVA Pharmaceutical Industries Ltd.
-
Integra LifeSciences Corporation
-
Medtronic PLC
-
Neuren Pharmaceuticals Ltd.
*Disclaimer: Major Players sorted in no particular order
Mild Traumatic Brain Injury Treatment Market Report - Table of Contents
-
1. INTRODUCTION
-
1.1 Study Deliverables
-
1.2 Study Assumptions
-
1.3 Scope of the Study
-
-
2. RESEARCH METHODOLOGY
-
3. EXECUTIVE SUMMARY
-
4. MARKET DYNAMICS
-
4.1 Market Overview
-
4.2 Market Drivers
-
4.2.1 Increasing Incidence Of Mild Traumatic Brain Injuries
-
4.2.2 Ongoing Product Development And Approval
-
-
4.3 Market Restraints
-
4.3.1 Stringent Regulatory Framework
-
4.3.2 Shortage Of Trained Professionals
-
-
4.4 Porter's Five Force Analysis
-
4.4.1 Threat of New Entrants
-
4.4.2 Bargaining Power of Buyers/Consumers
-
4.4.3 Bargaining Power of Suppliers
-
4.4.4 Threat of Substitute Products
-
4.4.5 Intensity of Competitive Rivalry
-
-
-
5. MARKET SEGMENTATION
-
5.1 By Treatment
-
5.1.1 Drugs
-
5.1.2 Surgery
-
-
5.2 End Users
-
5.2.1 Hospitals
-
5.2.2 Clinics
-
5.2.3 Others
-
-
5.3 Geography
-
5.3.1 North America
-
5.3.1.1 United States
-
5.3.1.2 Canada
-
5.3.1.3 Mexico
-
-
5.3.2 Europe
-
5.3.2.1 Germany
-
5.3.2.2 United Kingdom
-
5.3.2.3 France
-
5.3.2.4 Italy
-
5.3.2.5 Spain
-
5.3.2.6 Rest of Europe
-
-
5.3.3 Asia Pacific
-
5.3.3.1 China
-
5.3.3.2 Japan
-
5.3.3.3 India
-
5.3.3.4 Australia
-
5.3.3.5 South korea
-
5.3.3.6 Rest of Asia-Pacific
-
-
5.3.4 Middle East and Africa
-
5.3.4.1 GCC
-
5.3.4.2 South Africa
-
5.3.4.3 Rest of Middle East and Africa
-
-
5.3.5 South America
-
5.3.5.1 Brazil
-
5.3.5.2 Argentina
-
5.3.5.3 Rest of South America
-
-
-
-
6. COMPETITIVE LANDSCAPE
-
6.1 Company Profiles
-
6.1.1 Grace Laboratories LLC.
-
6.1.2 Integra LifeSciences Corporation
-
6.1.3 Medtronic PLC
-
6.1.4 Neuren Pharmaceuticals Ltd.
-
6.1.5 NeuroVive Pharmaceutical AB
-
6.1.6 Stemedica Cell Technologies Inc.
-
6.1.7 TEVA Pharmaceutical Industries Ltd.
-
6.1.8 Vasopharm GmbH
-
- *List Not Exhaustive
-
-
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
Mild Traumatic Brain Injury Treatment Industry Segmentation
As per the scope of the report, a patient with mild traumatic brain injury is a person who has had a traumatically induced physiological disruption of brain function. It has been recognized that patients with a mild traumatic brain injury can exhibit persistent emotional, cognitive, behavioral, and physical symptoms, alone or in combination, which may produce a functional disability.
By Treatment | |
Drugs | |
Surgery |
End Users | |
Hospitals | |
Clinics | |
Others |
Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Mild Traumatic Brain Injury Treatment Market Research FAQs
What is the current Mild Traumatic Brain Injury Treatment Market size?
The Mild Traumatic Brain Injury Treatment Market is projected to register a CAGR of 3.80% during the forecast period (2024-2029)
Who are the key players in Mild Traumatic Brain Injury Treatment Market?
NeuroVive Pharmaceutical AB, TEVA Pharmaceutical Industries Ltd., Integra LifeSciences Corporation, Medtronic PLC and Neuren Pharmaceuticals Ltd. are the major companies operating in the Mild Traumatic Brain Injury Treatment Market.
Which is the fastest growing region in Mild Traumatic Brain Injury Treatment Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Mild Traumatic Brain Injury Treatment Market?
In 2024, the North America accounts for the largest market share in Mild Traumatic Brain Injury Treatment Market.
What years does this Mild Traumatic Brain Injury Treatment Market cover?
The report covers the Mild Traumatic Brain Injury Treatment Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Mild Traumatic Brain Injury Treatment Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Traumatic Brain Injuries Treatment Industry Report
Statistics for the 2024 Traumatic Brain Injuries Treatment market share, size and revenue growth rate, created by Mordor Intelligenceā¢ Industry Reports. Traumatic Brain Injuries Treatment analysis includes a market forecast outlook 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.